![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 20, Issue 18, 4010-4020, September 15, 2009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
*Institute of Genetics, University of Bonn, D-53117 Bonn, Germany; ||Institute of Structural Biology (IBI-2), Research Center Jülich, D-52425 Jülich, Germany; and ¶Biochemistry and Cell Biology, School of Engineering and Science, Jacobs University Bremen, D-28759 Bremen, Germany
Submitted March 2, 2009;
Revised June 23, 2009;
Accepted July 14, 2009
Monitoring Editor: Kunxin Luo
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Le Bras et al., 2005). In addition, apoptosis is an important defense mechanism that protects organisms from pathogenesis of a variety of diseases including cancer, autoimmune disease, neurodegenerative disorders, and viral infections (Igney and Krammer, 2002; Debatin and Krammer, 2004; Clarke et al., 2005). The signaling pathways that lead to the initiation of programmed cell death converge in the activation of a proteolytic cascade involving aspartate-specific caspases that mediate the coordinated elimination of the apoptotic cell (Garrido and Kroemer, 2004; Riedl and Shi, 2004). Proapoptotic kinases play an essential role in the apoptotic signaling pathway. For example, overexpression of ASK1 (apoptosis signal-regulating kinase1) or the constitutively active form of ASK1 results in apoptosis induction in various cell types (Ichijo et al., 1997; Chang et al., 1998; Saitoh et al., 1998). Furthermore, it has been reported that a kinase-inactive mutant of ASK1 inhibits apoptosis induced by tumor necrosis factor-
, Fas ligation, or anticancer drugs (Chen et al., 1999; Kanamoto et al., 2000). Other kinases that can modulate the apoptotic response are RIP (receptor interacting protein), PKC
(protein kinase C delta), PITSLRE (member of the cyclin-dependent kinase superfamily), and DAPK (death-associated protein kinase; Deiss et al., 1995; Emoto et al., 1995; Lahti et al., 1995; Stanger et al., 1995; Meylan and Tschopp, 2005).
The DAPK family is a recently discovered group of highly related serine/threonine kinases that are involved in cell death signaling (Cohen and Kimchi, 2001; Kimchi, 2001). Three protein kinases of the DAPK family share 80% amino acid identity within their catalytic domains: DAPK, DAPK-related protein 1 (DRP-1), and DAP-like kinase (Dlk), which is also termed zipper-interacting protein kinase (ZIPK) or DAPK3 (Kawai et al., 1998; Kögel et al., 1998; Inbal et al., 2000; Shoval et al., 2007). A common feature in cell death induced by DAPK family members is the process of membrane blebbing which has been attributed to increased phosphorylation of the regulatory light chain of myosin II (MLC). MLC has been shown to be an in vitro substrate for all DAPK family members (Cohen et al., 1997; Kawai et al., 1998; Kögel et al., 1998; Sanjo et al., 1998; Kawai et al., 1999; Inbal et al., 2000; Debatin and Krammer, 2004). Experimental evidence further suggests that Dlk can mediate MLC phosphorylation in rat fibroblasts (Vetterkind et al., 2005b). This kinase has been implicated in apoptotic (Kögel et al., 1999; Page et al., 1999a; Kawai et al., 2003; Shani et al., 2004) as well as mitotic processes (Engemann et al., 2002; Preuss et al., 2003a,b). Although mitotic functions require a nuclear localization of the kinase, the proapoptotic potential of Dlk appears to correlate with enhanced cytoplasmic localization (Kögel et al., 1999; Page et al., 1999a; Shani et al., 2004). For example, a C-terminal Dlk deletion mutant defective for nuclear transport exhibited pronounced colocalization with actin filaments and high apoptotic activity in rat fibroblasts (Kögel et al., 1999). Furthermore, it has been shown that DAPK-mediated phosphorylation of ZIPK (the human orthologue of Dlk) results in predominantly cytoplasmic localization and greater cell death–inducing potency (Shani et al., 2004). The translocation of nuclear Dlk to the cytoplasm implies that Dlk-mediated apoptosis might depend on phosphorylation of a cytoplasmic downstream target.
A good candidate in this context is the proapoptotic protein Par-4 (prostate-apoptosis response-4) that was originally identified as an early response gene induced during apoptosis in prostate cancer cells (Sells et al., 1994). Protein complexes containing both Dlk and Par-4 have successfully been isolated from various cell types derived from different species (Page et al., 1999a; Kawai et al., 2003; Vetterkind and Morgan, 2009). However, direct interaction between the two proteins has only unambiguously been demonstrated for the murine system so far, where Par-4 is a direct interaction partner and in vitro substrate of Dlk (Page et al., 1999a). In fact, a recent report (Shoval et al., 2007) suggests that Par-4 binding may be a special feature of murine Dlk necessary to compensate for the evolutionary loss of regulatory phosphorylation sites, the phosphorylation of which is essential for cytoplasmic localization of ZIPK, the human orthologue of Dlk (Graves et al., 2005). Consistent with this hypothesis, coexpression of Par-4 and murine Dlk in rat fibroblasts leads to cytoplasmic accumulation of the kinase and Par-4–mediated recruitment to the actin cytoskeleton. Furthermore, enhanced MLC phosphorylation associated with a dramatic reorganization of the actin filament system and induction of apoptosis was observed (Vetterkind et al., 2005b). At present it is not entirely clear whether Dlk/Par-4 complex formation results from cytoplasmic retention of Dlk before nuclear entry or involves export of nuclear Dlk/Par-4 complexes. Both scenarios are conceivable because it has been shown that Par-4 localizes to the cytoplasm and the nucleus, albeit to different extents, depending on cell type and tissue (Boghaert et al., 1997; Sells et al., 1997; Guo et al., 1998; Page et al., 1999a; El-Guendy et al., 2003). As a consequence, it has been reported that Par-4 interacts with nuclear as well as cytoplasmic proteins (Diaz-Meco et al., 1996; Johnstone et al., 1996; Page et al., 1999a; Roussigne et al., 2003). In a nuclear complex with the transcription factor Wilms' tumor protein 1 (WT1), Par-4 acts as a transcriptional coregulator that represses the expression of the bcl-2 gene (Cheema et al., 2003). On the other hand, one of the cytoplasmic functions described for Par-4 is the inhibition of the protein kinase C isoform 
(PKC), thereby repressing PKC-mediated prosurvival signaling (Diaz-Meco et al., 1996; Wang et al., 2005).
The apoptotic activity of Par-4 has been confined to the C-terminal part of the protein, which contains a leucine zipper domain partially overlapping a death domain (Diaz-Meco et al., 1996; Johnstone et al., 1996; Rangnekar, 1998). Deletion of the leucine zipper resulted in the loss of proapoptotic activity and, conversely, overexpression of the leucine zipper domain had a dominant-negative effect by abrogating the proapoptotic function of full-length Par-4 (Sells et al., 1997). Ectopic expression of Par-4 is sufficient to induce apoptosis in several types of tumor cells (Chakraborty et al., 2001; Lucas et al., 2001; El-Guendy and Rangnekar, 2003), and it has been shown that a central domain of Par-4 that included NLS2 but lacked the leucine zipper domain (amino acids 137–195) can induce apoptosis in cancer cells (El-Guendy et al., 2003). This domain called SAC (for selective for apoptosis induction in cancer cells) contains a threonine residue (T155) that can be phosphorylated by protein kinase A (PKA) in vitro and appears to be critical for the proapoptotic function of Par-4 in cancer cells (Gurumurthy et al., 2005). In contrast, phosphorylation of a serine residue (S249) outside SAC near the Par-4 death domain by the kinase Akt (or protein kinase B) promotes cancer cell survival through selective sequestration of S249 phosphorylated Par-4 by binding to 14-3-3 proteins (Goswami et al., 2005). Taken together, these investigations suggest that phosphorylation is a key regulatory event which modulates Par-4 function.
Even though the cooperative effect of Dlk and Par-4 has been well documented in the past, the molecular mechanism how Dlk/Par-4 complexes trigger apoptosis in rat fibroblasts is not fully understood. In the present study we analyzed the functional relationship of Par-4 and Dlk in REF52.2 cells investigating Par-4 phosphorylation by Dlk and its cellular effects.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Construction of Plasmids
Cloning of Par-4-GFP, Par-4-CFP, FLAG-Par-4, Par-4 L3-GFP (green fluorescent protein), GFP-Dlk, and GFP-Dlk K42A has been described previously (Kögel et al., 1998; Kögel et al., 1999; Boosen et al., 2005; Vetterkind et al., 2005a,b). The cDNA sequence of Dlk was excised from the pGEX vector (Kögel et al., 1998) with restriction enzymes BamHI and XhoI and inserted into the vector pCMV-Tag2B (Stratagene, La Jolla, CA) to construct the FLAG-Dlk expression vector. For the generation of the yellow fluorescent protein (YFP)-Dlk construct, the cDNA sequence of enhanced YFP (EYFP) was excised from the pEYFP-C1 vector (BD Biosciences Clontech, Heidelberg, Germany) with restriction enzymes BsrGI and AgeI and subsequently subcloned into the GFP-Dlk vector. The Par-4 phosphorylation mutants carrying either an exchange of threonine or serine to alanine or both exchanges were generated by PCR site-directed mutagenesis using the Par-4 wild-type (wt) cDNA as template. In the first reaction the oligonucleotides Par-4 103–123 5'-AGCACCACGGACTTCCTGGAG-3' forward and Par-4 AgeI 5'-CCACCGGTCCCCTTGTCAGCTGCCC-3' reverse were used with primers harboring the desired mutation generating overlapping PCR fragments: Par-4 S154: forward, 5'-AAGCGCCGCGCTACCGGCGTG-3' and reverse, 5'-CACGCCGGTAGCGCGGCGCTT-3'; Par-4 T155A: forward, 5'-AAGCGCCGCTCCGCTGGCGTGGTCAAC-3' and reverse, 5'-GTTGACCACGCCAGCGGAGCG-3'; Par-4 S154A/T155A: forward, 5'- AAGCGCCGCGCAGCTGGCGTGGTCAAC-3' and reverse, 5'-CACGCCAGCTGCGCGGCG-3'; Par-4 S220A: forward, 5'-GCAGATACAAAGCCACAATCAGTGC-3' and reverse, 5'-GCACTGATTGTGGCTTTGTATCTGC-3'; Par-4 T155D: forward 5'-AAGCGCCGCTCCGACGGCGTGGTCAAC-3' and reverse, 5'-GTTGACCACGCCGTCGGAGCG-3'; and Par-4 T155E: forward, 5'-AAGCGCCGCTCCGAGGGCGTGGTCAAC-3' and reverse, 5'-GTTGACCACGCCCTCGGAGCG-3'.
In the second PCR reaction the resulting DNA fragments were assembled by PCR using the oligonucleotides Par-4 103–123 5'-AGCACCACGGACTTCCTGGAG-3' forward and Par-4 AgeI 5'-CCACCGGTCCCCTTGTCAGCTGCCC-3' reverse. The generated PCR products were digested with PshAI and EcoRV (for S154A and T155A), with PshAI and AccI (for S154/T155A) or with BssHII and AccI (for S220A) and subcloned into the Par-4 wt-GFP expression vector digested with restriction enzymes accordingly. For the generation of Par-4 mutant S249A the PCR reaction was carried out with oligonucleotides Par-4 S249A 5'-GCTTCAGTAGACACAACAGAGATACCGCCGCG-3' forward and Par-4 AgeI 5'-CCACCGGTCCCCTTGTCAGCTGCCC-3' reverse. The amplified PCR product was digested with AccI and AgeI and subsequently subcloned into the Par-4 wt-GFP expression vector. All mutations were confirmed by subsequent sequencing (AGOWA, Berlin, Germany).
Protein Expression and Purification
Cloning of the strep-tagged recombinant Par-4 wt protein has been described previously (Vetterkind et al., 2005b). For the generation of the strep-tagged Par-4 phosphorylation mutants S154A, T155A, S154/T155A, S220A, and S249A, the cDNA sequence was excised from the Par-4-GFP vector, respectively, with restriction enzymes BssHIIand EcoRV and subsequently subcloned into the pET23a(+) Par-4 wt vector. Strep-tagged full-length Par-4 and Par-4 mutants were expressed in the Escherichia coli strain BL21-CodonPlus DE3 (Stratagene). Bacteria were transformed with either Par-4 expression vector and grown in DYT-medium at 37°C. Protein expression was induced in late log phase with 1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG). Bacteria were harvested 3 h after induction and solubilized in buffer (50 mM Tris, pH 7.0, and 200 mM MgCl2) by ultrasonic disruption. Lysates were cleared from cell debris by centrifugation. Recombinant proteins were purified from the cell lysates using StrepTactin Sepharose (IBA, Göttingen, Germany) essentially according to the manufacturer's instructions.
In Vitro Phosphorylation Assay and Phosphoamino Acid Analysis
In vitro phosphorylation assays were carried out with purified recombinant Par-4 and Dlk in the presence of [
-32P]ATP essentially as described by Page et al. (1999a). For the phosphorylation reactions of Par-4 with PKA, 0.5 µM catalytic subunit of PKA (Calbiochem, La Jolla, CA) was used in the assay. In vitro–phosphorylated, radiolabeled Par-4 was separated on 10% SDS-PAGE and blotted onto nitrocellulose membrane. Radioactive bands were identified by autoradiography, isolated, and subjected to acid hydrolysis according to Preuss et al. (2003b). Phospho-serine and phospho-threonine (Sigma, St. Louis, MO) were used as internal standards and stained with ninhydrin. Radiolabeled phosphoamino acids were detected by autoradiography.
Antibody Generation
A phospho-specific antibody was raised in rabbits against a synthetic phospho-peptide of the sequence KRRSpTGVVN corresponding to residues 151–159 of rat Par-4 (Pineda Antibody Service, Berlin, Germany). The polyclonal anti-Phospho-Par-4(T155) antibody [denoted Par-4(P)T155] was affinity-purified on a peptide column.
Fluorescence Microscopy
For immunofluorescence analysis, cells were fixed 24 h after transfection with 3% formaldehyde in phosphate-buffered saline (PBS) for 20 min at room temperature and permeabilized with 0.1% Triton X-100 in PBS for 5 min. The cells were then treated with 5% nonfat dry milk for 1 h and stained with the Par-4(P)T155 antibody (Pineda Antibody Service) at 1:2000–1:8000 dilution and the mouse monoclonal anti-FLAG M2 antibody (Stratagene) at 1:5000 dilution for 1 h at room temperature. As secondary antibodies, Cy3-conjugated goat anti-mouse IgG or goat anti-rabbit IgG (Dianova, Hamburg, Germany) were used at 1:2000 dilution and incubated for 30 min. Actin filaments were stained with tetramethylrhodamine B isothiocyanate (TRITC)-conjugated phalloidin (Sigma) at room temperature for 15 min. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) for 15 min and subsequent washed with PBS. Cells were examined with an Axiophot fluorescence microscope (Carl Zeiss, Oberkochen, Germany) equipped with a CCD camera using filters optimized for double-label experiments and a 63x oil immersion objective. Confocal microscopy was performed with a Zeiss Axioplan fluorescence microscope coupled with a Zeiss LSM510. Images were processed with Adobe Photoshop 7.0 software (San Jose, CA).
Apoptosis Assay
At 24 h after transfection, REF52.2 cells were fixed with formaldehyde and stained with the monoclonal anti-FLAG M2 antibody (Stratagene) and with Cy3-conjugated goat anti-mouse IgG (Dianova) and with DAPI to visualize nuclei. The percentage of apoptotic cells that showed fragmented nuclei, condensed chromatin, and membrane blebbing was determined among the transfected cells by fluorescence microscopy, counting 100–200 positive cells in each experiment. Data were collected from at least three independent experiments. Statistical significance was determined in a two-tailed Student's t test.
Immunoprecipitation
REF52.2 cells were transiently transfected as described above. For some experiments, cells were subjected to either serum starvation for 16 h, or 16-h serum starvation followed by 15 min 10 µM lysophosphatidic acid (LPA; Cayman Chemical, Ann Arbor, MI), or 10 µM forskolin (Sigma) for 15 min. Twenty-four hours after transfection, the cells were washed in ice-cold PBS and lysed in isotonic lysis buffer (10 mM NaPO4, pH 8.0, 140 mM NaCl, 3 mM MgCl2, 1 mM dithiothreitol, 0.5% Nonidet-P40, and 50 µM leupeptin). The lysates were cleared by centrifugation and subjected to immunoprecipitation with the Par-4(P)T155-antibody (Pineda Antibody Service) or the mouse monoclonal anti-Par-4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), cross-linked to protein A or protein G agarose beads, at 4°C overnight. Immunoprecipitates were washed three times with lysis buffer and then subjected to SDS-PAGE according to standard protocols. For immunoprecipitation with the Par-4(P)T155-antibody, control experiments were performed using preimmune serum (Pineda Antibody Service).
Western Blot Analysis and Quantification of Par-4 Phosphorylation
Extract samples were separated on 10% SDS-PAGE (20 µg per lane) and electrophoretically transferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Residual protein-binding sites on the membrane were blocked with 5% nonfat dry milk in Tris-buffered saline/Tween. The membranes were incubated either with the mouse monoclonal anti-GFP antibody (Clontech) at 1:2000 dilution and the rabbit polyclonal anti-Par-4 antibody (Santa Cruz) at 1:2000 dilution. Bound antibodies were detected with peroxidase-conjugated secondary goat anti-mouse IgG or goat anti-rabbit at 1:5000 dilution (Dianova) using a SuperSignal West Pico chemoluminescence detection kit (Perbio Science, Bonn, Germany). Semiquantitative analysis of Par-4 phosphorylation was performed using densitometry. Par-4 bands after immunoprecipitation with the Par-4(P)T155 antibody were normalized to Par-4 bands in the respective input samples, and the phosphorylation level in unstimulated cells was defined as 100%. Significance was determined in a two-tailed paired Student's t test based on four independent experiments.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). These data suggest that the functional interplay of both proteins in apoptosis induction is influenced by phosphorylation events. In agreement with these observations, coexpression of GFP-tagged Par-4 and FLAG-tagged Dlk wt constructs (denoted Par-4 wt-GFP and FLAG-Dlk wt) in REF52.2 cells (Figure 1, a–d) resulted in a clear colocalization of both proteins at actin filaments (merged image Figure 1d) and the induction of apoptosis (condensed and fragmented nuclei Figure 1c). GFP-tagging neither affects Par-4 localization (Vetterkind et al., 2005b) nor does the tag interfere with binding to known cellular ligands (Supplemental Figure S1, Supplemental Material). We next used the leucine zipper point mutant Par-4 L3-GFP (Boosen et al., 2005) containing three exchanges of leucine residues to alanines in the coiled coil interface. As expected, this mutant failed to recruit FLAG-Dlk wt to the microfilament system (Figure 1, e–h) as indicated by the prominent nuclear localization of the kinase (Figure 1f) and impaired induction of apoptosis (Figure 1g). Additionally, we analyzed a kinase-inactive point mutant, FLAG-Dlk K42A, which harbors an exchange of lysine to alanine at position 42 of rat Dlk (Kögel et al., 1998). As shown previously (Page et al., 1999a), the kinase-inactive mutant FLAG-Dlk K42A (Figure 1, i–l) remained in the nucleus and did not colocalize with Par-4 wt-GFP at actin filaments. Again, the prevention of Dlk/Par-4 complex formation resulted in impaired apoptosis induction. These analyses not only confirm that both, Dlk/Par-4 complex formation and the catalytic activity of Dlk are corequisites for Par-4/Dlk–mediated apoptosis, but also suggest that Par-4 may be an immediate downstream target of Dlk.
|
). Because a C-terminal truncation mutant of Dlk has been shown to phosphorylate Par-4 in an in vitro phosphorylation assay (Page et al., 1999a), we analyzed the rat Par-4 amino acid sequence for such motifs. Three potential Dlk phosphorylation sites could be identified, which are all located in the C-terminal half of the protein between the second nuclear localization signal (NLS2) and the death domain (Figure 2A): a single threonine residue at position 155 (T155) and two serine residues at positions 220 and 249 (Figure 2A). Because the consensus sequence comprising T155 also included a serine residue at position 154 (S154) and the required arginine residue in this area is surrounded by other basic residues, we also considered S154 as putative Dlk phosphorylation site. The Par-4 sequences were compared with those of known substrates of Dlk/ZIPK (Burch et al., 2004), which all harbor an arginine residue at the –3 position preceding either a serine or threonine phospho-acceptor site, which are neighbored by polar rather than hydrophobic amino acid residues (Figure 2B). Because the same holds true for the putative phosphorylation sites on Par-4, we decided to analyze all of them in Dlk phosphorylation assays.
|
). Purified recombinant Par-4 protein (0.5–1 µg) was phosphorylated either by Dlk or PKA in the presence of [-32P]ATP. Samples were taken after 1-, 5-, 10-, and 30-min incubation, and aliquots were analyzed by SDS-PAGE and autoradiography. As shown in Figure 3A, Par-4 was rapidly phosphorylated by recombinant Dlk with a faint band already visible after 1 min (Figure 3A, lane 2), which continuously increased in intensity resulting in a prominent phosphorylation after 30 min (Figure 3A, lane 5). A radioactive band at the position of Dlk (52 kDa) indicates that the kinase undergoes autophosphorylation. In a second set of experiments (Figure 3A, lanes 6–8) we included the recombinant kinase-inactive mutant Dlk K42A, which had been purified in a manner analogous to Dlk wt. Even after 30 min Par-4 was not phosphorylated when Dlk K42A was used in the phosphorylation assay (Figure 3A, lane 8), demonstrating that Par-4 phosphorylation in this assay was only dependent on recombinant Dlk kinase activity. In addition, no autophosphorylation was observed in contrast to Dlk wt in the absence (Figure 3A, lane 6) and presence (Figure 3A, lane 7) of Par-4. As expected, Par-4 could also be phosphorylated by PKA in vitro (Figure 3B, lanes 9–13). Subsequent phosphoamino acid analysis of the phosphorylated Par-4 protein bands revealed that Par-4 had been phosphorylated at threonine and serine residues by Dlk (Figure 3C) but only at serine residues by PKA (Figure 3D). The latter finding was surprising as it contradicted a previous report in which residue T155 of Par-4 had been suggested to be a phosphorylation site for PKA (Gurumurthy et al., 2005).
|
|
15% in T155A/Dlk coexpressing cells, which was significantly lower than apoptosis induction in cells coexpressing Par-4 wt and Dlk (69% apoptotic cells) or any of the other Par-4 mutants (69% for S154A/Dlk, 76% for S220A/Dlk, and 79% for S249A/Dlk). These data demonstrate that phosphorylation of Par-4 at T155 is crucial for Dlk/Par-4–mediated apoptosis in rat fibroblasts.
T155 Is the Preferred Residue Phosphorylated by Dlk In Vitro
Because apoptosis induction by Par-4 and Dlk strongly depended on Par-4 phosphorylation at T155 (Figure 4) as well as catalytically active Dlk (Figure 1), mainly phosphorylating threonine residues in vitro (Figure 3C), we next analyzed whether Par-4 was indeed phosphorylated by Dlk at residue T155. Therefore, recombinant Par-4 proteins and Dlk were used in in vitro phosphorylation assays as already described above. Samples were subjected to SDS-PAGE and subsequent autoradiography (Figure 5, top panel). Although Par-4 wt and mutant Par-4 S154A were phosphorylated to similar extents (Figure 5, top panel, cf. lanes 1 and 2), only a faint radioactive band was observed for the Par-4 T155A mutant (Figure 5, top panel, lane 3), demonstrating that T155A was in fact the main site phosphorylated by Dlk in vitro. Phosphate incorporation was even further reduced in the Par-4 S154A/T155A double mutant (Figure 5, top panel, lane 4), suggesting some phosphorylation of S154 in the T155A mutant, even though this serine residue is not located in a perfect Dlk consensus sequence. The Coomassie staining of the same gel is shown in the bottom panel of Figure 5, demonstrating equal protein load.
|
|
70 kDa corresponding to the GFP-tagged Par-4 proteins from lysates of cells cotransfected with Par-4 wt/Dlk (Figure 6B, lane 3) and Par-4 S154A/Dlk (Figure 6B, lane 5), but not from lysates derived from cells that had been transfected either with Par-4-GFP wt or Par-4 S154A-GFP alone (Figure 6, lanes 2 and 4, respectively). No protein was immunoprecipitated from Par-4 T155A-GFP/Dlk cotransfected cells (Figure 6, lane 7) and from cells expressing either Par-4 T155A-GFP or the GFP-vector alone (Figure 6, lanes 6 and 1, respectively). Similar expression levels of the Par-4 constructs were confirmed by SDS-PAGE and Western blotting with a GFP antibody analyzing 20 µg of total protein of each cell lysate (Figure 6B, bottom row).
The Cellular Effect of T155 Phosphorylation Cannot Be Mimicked by Acidic Amino Acids
A common strategy of mimicking constitutive phosphorylation of a protein is the substitution of serine and threonine residues by acidic amino acids. We thus generated C-terminally GFP-tagged phospho-mutants of Par-4 carrying either an exchange of an aspartic acid residue or a glutamic acid residue at position 155 of the rat Par-4 amino acid sequence (denoted Par-4 T155D-GFP or Par-4 T155E-GFP, respectively). Hence, we tested both phospho-mutants for induction of apoptosis in conjunction with Dlk in REF52.2 cells (Figure 7). Both Par-4 phospho-mutants clearly colocalized with the actin filament system (Figure 7, a and e). However, both Par-4 mutants failed to recruit the coexpressed FLAG-Dlk construct, which was mainly retained in the nucleus of the cotransfected cells (Figure 7, b and f). Furthermore, no induction of apoptosis was observed. Thus introducing acidic amino acids at position 155 in the rat Par-4 amino acid sequence at residue T155 is not sufficient to trigger Par-4/Dlk–induced apoptosis.
|
; Hsu et al., 2002), thus complicating normalization of the phosphorylation status with respect to total Par-4 levels. It has recently been shown that Dlk becomes activated by ROCK via phosphorylation at threonine-265 (Hagerty et al., 2007), a conserved phosphorylation site that is critical for kinase activity (Sato et al., 2006). Consequently, treatment with the Rho/ROCK activator LPA eventually leads to Dlk activation. Hence REF52.2 cells were serum-starved for 16 h and then treated with LPA for 15 min (Figure 8A, lane 4). These cells were compared with untreated cells (Figure 8A, lane 2), and samples exposed to serum starvation only (Figure 8A, lane 3) and to cultures that had been treated with forskolin to increase endogenous cAMP levels to activate PKA (Figure 8A, lane 5). None of the cultures underwent apoptosis, as judged by immunofluorescence analyses (data not shown). Cell lysates were subjected to immunoprecipitation with the phospho-specific Par-4(P)155 antibody and the immunoprecipitated protein was compared with total Par-4 expression levels (Figure 8, input in bottom row). Neither serum starvation alone nor PKA activation by forskolin led to an increase in Par-4 phosphorylation at T155. In contrast, a significantly higher level of endogenous Par-4 phosphorylation was achieved by serum starvation in combination with LPA treatment as revealed by densitometric analysis of four independent experiments (Figure 8B), suggestive of enhanced phosphorylation by Dlk. Unfortunately, there are currently no specific inhibitors of Dlk available allowing clear distinction between the effect of ROCK and Dlk. Therefore at present we can only speculate that endogenous Par-4 is phosphorylated at threonine-155 by Dlk after LPA stimulation.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). In the present study we show that Par-4 itself is an in vivo downstream target of Dlk and that enhanced Par-4 phosphorylation by Dlk at T155 is an important step for promoting apoptosis in REF52.2 cells. The importance of T155 phosphorylation in Par-4–mediated apoptosis is corroborated by earlier investigations on the role of Par-4 in apoptosis induction in cancer cells (Gurumurthy et al., 2005). In contrast to our findings, however, the authors suggested PKA to be responsible for T155 phosphorylation as PKA activity was significantly enhanced in the prostate cancer cell lines investigated. In addition, using NIH3T3/Ras transformed cells in transfection experiments they showed that in vivo phosphorylation of a Par-4 deletion construct (137–187) was abolished upon addition of the PKA inhibitory peptide PKI. In vitro phosphorylation of immunoprecipitated Par-4 constructs by recombinant PKA also revealed a significant decrease in phosphate incorporation into a T155A mutant in the same study (Gurumurthy et al., 2005). The latter finding clearly contradicts our own in vitro phosphorylation analyses using recombinant proteins only. In contrast to recombinant Dlk, which preferentially phosphorylated Par-4 at T155, phosphoamino acid analyses revealed that PKA only phosphorylated serine residues on recombinant Par-4 protein, suggesting that T155 is not an in vitro target for PKA. In addition, neither the application of a PKA inhibitor (unpublished observations) nor stimulation of PKA via forskolin (Figure 8) had any effect on T155 phosphorylation in rat fibroblasts. Different cell types (e.g., prostate cancer cells and rat fibroblasts) may exhibit different kinase activities leading to Par-4 phosphorylation at T155, thus explaining how modulating PKA activity may affect Par-4 phosphorylation in one cell type but not the other. Furthermore, Dlk/Par-4 complex formation may not occur to similar extents in all cell types and species (Shoval et al., 2007 and see below). However, the discrepancies regarding the in vitro phosphorylation data cannot satisfactorily explained at present. In any case, it is clear that in REF52.2 cells, Dlk and not PKA is the kinase responsible for Par-4 phosphorylation at T155 leading to the induction of apoptosis in these cells.
Interestingly, the phosphorylation event seems to be intimately correlated with Dlk recruitment to the microfilament system, which is an important step during Par-4 apoptosis induction in rat fibroblasts (Vetterkind et al., 2005b). The cytoskeletal association is also indicative of Dlk/Par-4 complex formation, even though at present it remains unclear whether this association occurs prior or at the same time with actin filament binding. In our study, complex formation was clearly impaired, if either a kinase-dead Dlk mutant was used or T155 was mutated into a nonphosphorylatable residue. In both cases, a prominent nuclear localization was observed for Dlk proteins, whereas the Par-4 constructs always associated with cellular stress fibers. In this context, it is important to note that a decrease in Dlk/Par-4 complex formation and consequently significantly lower apoptosis induction was observed for any mutation of T155, irrespective of whether T155 had been mutated into alanine or into acidic residues, mimicking dephosphorylated and phosphorylated Par-4 proteins, respectively. These findings suggest that the phosphorylation event is coupled to the stabilization of the Par-4/Dlk complex and association with the actin cytoskeleton. The exact molecular mechanism how T155 phosphorylation of Par-4 may contribute to complex stability remains to be elucidated, but it is an attractive model allowing prolonged anchorage of the kinase to the actin cytoskeleton, which could support the cytoskeletal reorganization during apoptosis, e.g., leading to a more efficient phosphorylation of MLC.
Stable Dlk/Par-4 complexes may also explain how Dlk compensates for the lack of a death domain and other structural features present in the related family member DAPK: Even though Dlk and DAPK show high sequence homology in the N-terminal kinase domains, they both significantly differ in size and domain structure in the extracatalytic domains. The 160-kDa protein DAPK harbors a Ca2+/CaM-binding autoregulatory domain, eight ankyrin repeats, two P-loop motifs followed by a cytoskeletal binding region, and a C-terminal death domain (Bialik and Kimchi, 2006). The ankyrin repeats and the cytoskeletal binding region have been shown to direct DAPK to the actin cytoskeleton, whereas the death domain is an important regulator of DAPK activity. In contrast, the extracatalytic region of Dlk neither contains any element allowing for cytoskeletal association nor does it harbor a death domain. Instead, Dlk contains two NLSs), an arginine-rich domain (amino acids 338–417) mediating the binding to Par-4 (Page et al., 1999a), and a leucine zipper mediating homodimerization and interactions with other partners (Page et al., 1999b; Engemann et al., 2002). Because Par-4 binds to actin filaments and contains a C-terminal death domain, the Dlk/Par-4 complex can be thought of as a bipartite structural mimic of DAPK (Bialik and Kimchi, 2006). Stabilization of this complex through T155 phosphorylation by Dlk would thus clearly be advantageous for apoptosis induction. A potential stabilizing effect of T155 phosphorylation on Dlk/Par-4 complexes would also be beneficial in other cell systems where Dlk and Par-4 have been suggested to exert their proapoptotic effects in the nucleus. Finally, there is even functional evidence suggesting that Dlk/Par-4 complexes exhibit similar properties as compared with DAPK. For the latter it has been shown that the isolated death domain acts as a dominant negative mutant when expressed in eukaryotic cells (Cohen et al., 1999; Raveh et al., 2000), whereas deletion of this region may attenuate the kinase's proapoptotic activity (Cohen et al., 1999; Kuo et al., 2003). In analogy, studies have demonstrated that overexpression of the Par-4 leucine zipper domain partially overlapping with the protein's death domain also prevents apoptosis induction in a dominant negative manner (Sells et al., 1997). Deletion of the leucine zipper domain abrogates the proapoptotic function of Par-4, suggesting that this domain is essential for the proapoptotic activity of the protein (Sells et al., 1997). In REF52.2 cells the C-terminus of Par-4 (aa 266–332) does not bind to actin filaments, both in vitro and vivo (Vetterkind et al., 2005b) and thus fails to recruit Dlk to the microfilament system, leading to a decrease in apoptosis. For both scenarios it is fair to assume that the C-terminal domains of the death-inducing proteins DAPK and Par-4 compete with endogenous DAPK and Dlk/Par-4 complexes, respectively, by sequestering apoptosis-relevant interaction partners.
It has recently been shown that murine Dlk but not the human orthologue ZIPK directly binds to Par-4 (Shoval et al., 2007). The authors speculate that the cytoplasmic retention of murine Dlk by Par-4 compensates for the evolutionary loss of threonine 299, a highly conserved phosphorylation site in all nonmurine species investigated so far. Phosphorylation at threonine-299 is crucial for cytoplasmic localization of ZIPK (Graves et al., 2005). The loss of threonine-299 in murine Dlk not only explains the predominant nuclear localization of Dlk in the absence of sufficiently high Par-4 concentrations, but also the need for a different regulatory mechanism mediating cytoplasmic retention of Dlk. In general, murine Dlk shows a much higher sequence divergence from the human orthologue ZIPK in the extra-catalytic domain than any other ZIPK protein, even from more distantly related vertebrates (Shoval et al., 2007). This sequence diversity also accounts for the Par-4 binding property of Dlk but not ZIPK. Whether this interaction is indeed a unique feature of murine rodents remains to be shown. At least in ferrets, for which the protein sequence of Dlk is not known yet, Dlk was shown to colocalize with endogenous Par-4 on actin filaments in differentiated vascular smooth muscle cells (Vetterkind and Morgan, 2009). Even in human ARPE19 cells that have a much more pronounced microfilament system than the HeLa cells investigated (Shoval et al., 2007), an association of ZIPK with the microfilament system was observed (Takamoto et al., 2006). Taken together, these data suggest that in different species ZIPK protein recruitment to the microfilament system is achieved by different proteins: Although Par-4 functions as the predominant recruitment factor for Dlk in murine cells, human ZIPK may be targeted to microfilaments via different proteins, yet to be identified. The outcome, however, is the same in both cases: a stable association of either kinase with a microfilament-associated protein eventually leads to the phosphorylation of MLC, the regulatory light chain of myosin II, responsible for inducing major cytoskeletal changes during apoptosis (Murata-Hori et al., 2001; Vetterkind et al., 2005b).
At first glance, a quite unexpected finding was the basal phosphorylation level of endogenous Par-4 at T155 in untreated Ref52.2 cells, a phenomenon not observed when analyzing ectopically expressed Par-4 constructs in the absence of exogenous Dlk (Figure 6B). In addition, neither basal phosphorylation of overexpressed Par-4 wt-CFP (Figure 6Ao) nor enhanced phosphorylation of endogenous Par-4 at T155 after serum starvation and LPA treatment lead to the induction of apoptosis (Figure 8 and data not shown). However, these findings are in good agreement with several previous observations: 1) Dlk/Par-4–containing complexes have been shown to facilitate contraction in differentiated vascular smooth muscle cells by regulating MLC phosphorylation, indicating that both proteins may also function as physiological modulators of the microfilament system (Vetterkind and Morgan, 2009). 2) Neither Dlk nor Par-4 overexpression alone activates apoptotic pathways in rodent fibroblasts (Kögel et al., 1999; Page et al., 1999a; Gurumurthy et al., 2005), suggesting that endogenous expression levels in nonapoptotic fibroblasts do not suffice to generate high enough concentrations of Dlk/Par-4 complexes, allowing initiation of apoptosis. 3) Apoptosis induction by ionomycin (Sells et al., 1994) or thapsigargin (Hsu et al., 2002) is accompanied by an increase in Par-4 expression. Taken together, these findings suggest a certain threshold in Dlk/Par-4 complex formation that needs to be overcome for apoptosis induction. Alternatively, additional phosphorylation of Par-4 at sites other than T155 may further influence the proapoptotic function of Dlk/Par-4 complexes (see below).
So far, we have only discussed T155 phosphorylation with respect to its effect on Par-4 association with Dlk. However, phosphorylation might be a more general regulatory mechanism in regulating Par-4–mediated apoptosis (Goswami et al., 2005; Gurumurthy et al., 2005). Although prominent T155 phosphorylation clearly promotes apoptosis in both, REF52.2 fibroblasts (this report) and cancer cells (Gurumurthy et al., 2005), phosphorylation at serine-249 by Akt, a key cell survival kinase has been reported to attenuate Par-4–induced apoptosis (Goswami et al., 2005). Again, these studies were performed in cancer cell lines where nuclear translocation of Par-4 is crucial for apoptosis induction. Here the authors suggested that the anti-apoptotic effect of Akt on Par-4 is based on the interaction of phosphorylated Par-4 with 14-3-3 proteins, which are well established as molecular sequestration sites for cell death promoters. Binding to 14-3-3 leads to Par-4 retention within the cytoplasm, thus preventing the induction of apoptosis. Interestingly, Par-4 phosphorylation by Akt also depends on both, kinase activity of Akt and the presence of the S249 phosphorylation site suggesting that, again, phosphorylation is coupled to stable complex formation.
Taken together, these data reveal that Par-4 is an in vivo substrate for proapoptotic (Dlk) as well as antiapoptotic (Akt) kinases and that Par-4 phosphorylation leads to the formation and/or stabilization of protein complexes either initiating apoptosis or promoting cell survival. Hence, Par-4 could function as a molecular switch between these two cell fates by reflecting the endogenous balance between proapoptotic and antiapoptotic signals through its phosphorylation state.
|
ACKNOWLEDGMENTS |
|---|
|
Footnotes |
|---|
These authors contributed equally to this work. 
Present addresses: 
Institute of Pharmacology and Toxicology, University Hospital of Johann Wolfgang Goethe-University of Frankfurt am Main, D-60590 Frankfurt am Main, Germany;
Institute of Health Sciences, Sargent College, Boston University, Boston, MA 02215.
Address correspondence to: Ute Preuss (u.preuss{at}uni-bonn.de).
Abbreviations used: Par-4, prostate apoptosis response-4; Dlk, DAP-like kinase; MLC, myosin light chain.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Boghaert, E. R., Sells, S. F., Walid, A. J., Malone, P., Williams, N. M., Weinstein, M. H., Strange, R., and Rangnekar, V. M. (1997). Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 8, 881–890.[Abstract]
Boosen, M., Vetterkind, S., Koplin, A., Illenberger, S., and Preuss, U. (2005). Par-4-mediated recruitment of Amida to the actin cytoskeleton leads to the induction of apoptosis. Exp. Cell Res 311, 177–191.[CrossRef][Medline]
Burch, L. R., Scott, M., Pohler, E., Meek, D., and Hupp, T. (2004). Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1. J. Mol. Biol 337, 115–128.[CrossRef][Medline]
Chakraborty, M., Qiu, S. G., Vasudevan, K. M., and Rangnekar, V. M. (2001). Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61, 7255–7263.
Chang, H. Y., Nishitoh, H., Yang, X., Ichijo, H., and Baltimore, D. (1998). Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281, 1860–1863.
Cheema, S. K., Mishra, S. K., Rangnekar, V. M., Tari, A. M., Kumar, R., and Lopez-Berestein, G. (2003). Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J. Biol. Chem 278, 19995–20005.
Chen, Z., Seimiya, H., Naito, M., Mashima, T., Kizaki, A., Dan, S., Imaizumi, M., Ichijo, H., Miyazono, K., and Tsuruo, T. (1999). ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene 18, 173–180.[CrossRef][Medline]
Clarke, P., Richardson-Burns, S. M., DeBiasi, R. L., and Tyler, K. L. (2005). Mechanisms of apoptosis during reovirus infection. Curr. Top. Microbiol. Immunol 289, 1–24.[CrossRef][Medline]
Cohen, O., Feinstein, E., and Kimchi, A. (1997). DAP-kinase is a Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 16, 998–1008.[CrossRef][Medline]
Cohen, O., Inbal, B., Kissil, J. L., Raveh, T., Berissi, H., Spivak-Kroizaman, T., Feinstein, E., and Kimchi, A. (1999). DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J. Cell Biol 146, 141–148.
Cohen, O., and Kimchi, A. (2001). DAP-kinase: from functional gene cloning to establishment of its role in apoptosis and cancer. Cell Death Differ 8, 6–15.[CrossRef][Medline]
Debatin, K. M., and Krammer, P. H. (2004). Death receptors in chemotherapy and cancer. Oncogene 23, 2950–2966.[CrossRef][Medline]
Deiss, L. P., Feinstein, E., Berissi, H., Cohen, O., and Kimchi, A. (1995). Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9, 15–30.
Diaz-Meco, M. T., Municio, M. M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L., and Moscat, J. (1996). The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86, 777–786.[CrossRef][Medline]
El-Guendy, N., and Rangnekar, V. M. (2003). Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp. Cell Res 283, 51–66.[CrossRef][Medline]
El-Guendy, N., Zhao, Y., Gurumurthy, S., Burikhanov, R., and Rangnekar, V. M. (2003). Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol. Cell. Biol 23, 5516–5525.
Emoto, Y. et al. (1995). Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14, 6148–6156.[Medline]
Engemann, H., Heinzel, V., Page, G., Preuss, U., and Scheidtmann, K. H. (2002). DAP-like kinase interacts with the rat homolog of Schizosaccharomyces pombe CDC5 protein, a factor involved in pre-mRNA splicing and required for G2/M phase transition. Nucleic Acids Res 30, 1408–1417.
Garrido, C., and Kroemer, G. (2004). Life's smile, death's grin: vital functions of apoptosis-executing proteins. Curr. Opin. Cell Biol 16, 639–646.[CrossRef][Medline]
Goswami, A., Burikhanov, R., de Thonel, A., Fujita, N., Goswami, M., Zhao, Y., Eriksson, J. E., Tsuruo, T., and Rangnekar, V. M. (2005). Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol. Cell 20, 33–44.[CrossRef][Medline]
Graves, P. R., Winkfield, K. M., and Haystead, T. A. (2005). Regulation of zipper-interacting protein kinase activity in vitro and in vivo by multisite phosphorylation. J. Biol. Chem 280, 9363–9374.
Guo, Q., Fu, W., Xie, J., Luo, H., Sells, S. F., Geddes, J. W., Bondada, V., Rangnekar, V. M., and Mattson, M. P. (1998). Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. Nat. Med 4, 957–962.[CrossRef][Medline]
Gurumurthy, S., Goswami, A., Vasudevan, K. M., and Rangnekar, V. M. (2005). Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell. Biol 25, 1146–1161.
Hagerty, L., Weitzel, D. H., Chambers, J., Fortner, C. N., Brush, M. H., Loiselle, D., Hosoya, H., and Haystead, T. A. (2007). ROCK1 phosphorylates and activates zipper-interacting protein kinase. J. Biol. Chem 282, 4884–4893.
Hsu, S. C., Kirschenbaum, F., Miller, J., Cordell, B., and McCarthy, J. V. (2002). Structural and functional characterization of the upstream regulatory region of the human gene encoding prostate apoptosis response factor-4. Gene 295, 109–116.[CrossRef][Medline]
Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275, 90–94.
Igney, F. H., and Krammer, P. H. (2002). Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277–288.[CrossRef][Medline]
Inbal, B., Shani, G., Cohen, O., Kissil, J. L., and Kimchi, A. (2000). Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol. Cell. Biol 20, 1044–1054.
Johnstone, R. W. et al. (1996). A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol. Cell. Biol 16, 6945–6956.
Kanamoto, T., Mota, M., Takeda, K., Rubin, L. L., Miyazono, K., Ichijo, H., and Bazenet, C. E. (2000). Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons. Mol. Cell. Biol 20, 196–204.
Kawai, T., Akira, S., and Reed, J. C. (2003). ZIP kinase triggers apoptosis from nuclear PML oncogenic domains. Mol. Cell. Biol 23, 6174–6186.
Kawai, T., Matsumoto, M., Takeda, K., Sanjo, H., and Akira, S. (1998). ZIP kinase, a novel serine/threonine kinase which mediates apoptosis. Mol. Cell. Biol 18, 1642–1651.
Kawai, T., Nomura, F., Hoshino, K., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Akira, S. (1999). Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity. Oncogene 18, 3471–3480.[CrossRef][Medline]
Kimchi, A. (2001). A cell death-promoting kinase. Nat. Struct. Biol 8, 824–826.[CrossRef][Medline]
Kögel, D., Bierbaum, H., Preuss, U., and Scheidtmann, K. H. (1999). C-terminal truncation of Dlk/ZIP kinase leads to abrogation of nuclear transport and high apoptotic activity. Oncogene 18, 7212–7218.[CrossRef][Medline]
Kögel, D., Plöttner, O., Landsberg, G., Christian, S., and Scheidtmann, K. H. (1998). Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones. Oncogene 17, 2645–2654.[CrossRef][Medline]
Kuo, J. C., Lin, J. R., Staddon, J. M., Hosoya, H., and Chen, R. H. (2003). Uncoordinated regulation of stress fibers and focal adhesions by DAP kinase. J. Cell Sci 116, 4777–4790.
Lahti, J. M., Xiang, J., and Kidd, V. J. (1995). The PITSLRE protein kinase family. Prog. Cell Cycle Res 1, 329–338.[Medline]
Le Bras, M., Clement, M. V., Pervaiz, S., and Brenner, C. (2005). Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol. Histopathol 20, 205–219.[Medline]
Lucas, T. et al. (2001). Differential expression levels of Par-4 in melanoma. Melanoma Res 11, 379–383.[CrossRef][Medline]
Meylan, E., and Tschopp, J. (2005). The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci 30, 151–159.[CrossRef][Medline]
Murata-Hori, M., Fukuta, Y., Ueda, K., Iwasaki, T., and Hosoya, H. (2001). HeLa ZIP kinase induces diphosphorylation of myosin II regulatory light chain and reorganization of actin filaments in nonmuscle cells. Oncogene 20, 8175–8183.[CrossRef][Medline]
Page, G., Kögel, D., Rangnekar, V., and Scheidtmann, K. H. (1999a). Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 18, 7265–7273.[CrossRef][Medline]
Page, G., Lödige, I., Kögel, D., and Scheidtmann, K. H. (1999b). AATF, a novel transcription factor that interacts with Dlk/ZIP kinase and interferes with apoptosis. FEBS Lett 462, 187–191.[CrossRef][Medline]
Preuss, U., Bierbaum, H., Buchenau, P., and Scheidtmann, K. H. (2003a). DAP-like kinase, a member of the death-associated protein kinase family, associates with centrosomes, centromers, and the contractile ring during mitosis. Eur. J. Cell Biol 82, 447–459.[CrossRef][Medline]
Preuss, U., Landsberg, G., and Scheidtmann, K. H. (2003b). Novel mitosis-specific phosphorylation of histone H3 at Thr11 mediated by Dlk/ZIP kinase. Nucleic Acids Res 31, 878–885.
Rangnekar, V. M. (1998). Apoptosis mediated by a novel leucine zipper protein Par-4. Apoptosis 3, 61–66.[CrossRef][Medline]
Raveh, T., Berissi, H., Eisenstein, M., Spivak, T., and Kimchi, A. (2000). A functional genetic screen identifies regions at the C-terminal tail and death-domain of death-associated protein kinase that are critical for its proapoptotic activity. Proc. Natl. Acad. Sci. USA 97, 1572–1577.
Riedl, S. J., and Shi, Y. (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol 5, 897–907.[CrossRef][Medline]
Roussigne, M., Cayrol, C., Clouaire, T., Amalric, F., and Girard, J. P. (2003). THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies. Oncogene 22, 2432–2442.[CrossRef][Medline]
Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., and Ichijo, H. (1998). Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17, 2596–2606.[CrossRef][Medline]
Sanjo, H., Kawai, T., and Akira, S. (1998). DRAKs, novel serine/threonine kinases related to death-associated protein kinase that trigger apoptosis. J. Biol. Chem 273, 29066–29071.
Sato, N. et al. (2006). Phosphorylation of threonine-265 in Zipper-interacting protein kinase plays an important role in its activity and is induced by IL-6 family cytokines. Immunol. Lett 103, 127–134.[CrossRef][Medline]
Sells, S. F. et al. (1997). Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol. Cell. Biol 17, 3823–3832.
Sells, S. F., Wood, D. P., Jr., Joshi-Barve, S. S., Muthukumar, S., Jacob, R. J., Crist, S. A., Humphreys, S., and Rangnekar, V. M. (1994). Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5, 457–466.[Abstract]
Shani, G., Marash, L., Gozuacik, D., Bialik, S., Teitelbaum, L., Shohat, G., and Kimchi, A. (2004). Death-associated protein kinase phosphorylates ZIP kinase, forming a unique kinase hierarchy to activate its cell death functions. Mol. Cell. Biol 24, 8611–8626.
Shoval, Y., Pietrokovski, S., and Kimchi, A. (2007). ZIPK: a unique case of murine-specific divergence of a conserved vertebrate gene. PLoS Genet 3, 1884–1893.[Medline]
Stanger, B. Z., Leder, P., Lee, T. H., Kim, E., and Seed, B. (1995). RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81, 513–523.[CrossRef][Medline]
Takamoto, N., Komatsu, S., Komaba, S., Niiro, N., and Ikebe, M. (2006). Novel ZIP kinase isoform lacks leucine zipper. Arch. Biochem. Biophys 456, 194–203.[CrossRef][Medline]
Vaux, D. L., and Strasser, A. (1996). The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA 93, 2239–2244.
Vetterkind, S., Boosen, M., Scheidtmann, K. H., and Preuss, U. (2005a). Ectopic expression of Par-4 leads to induction of apoptosis in CNS tumor cell lines. Int. J. Oncol 26, 159–167.[Medline]
Vetterkind, S., Illenberger, S., Kubicek, J., Boosen, M., Appel, S., Naim, H. Y., Scheidtmann, K. H., and Preuss, U. (2005b). Binding of Par-4 to the actin cytoskeleton is essential for Par-4/Dlk-mediated apoptosis. Exp. Cell Res 305, 392–408.[CrossRef][Medline]
Vetterkind, S., and Morgan, K. G. (2009). The pro-apoptotic protein Par-4 facilitates vascular contractility by cytoskeletal targeting of Zipk. J. Cell Mol. Med 13, 887–895.[CrossRef][Medline]
Wang, G., Silva, J., Krishnamurthy, K., Tran, E., Condie, B. G., and Bieberich, E. (2005). Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem 280, 26415–26424.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
